|
|
|
|
|
The Niche Stem Cell & Regen Med Website
|
We have a new post today!
|
|
|
Weekly reads: KRAS G12C, eLife journal controversy, bird iPSCs
|
|
|
|
If you've never heard of the KRAS G12C mutation, it's a particularly frightening mutation present in numerous cancers. Like the MYC oncogene, many people view mutations in RAS as undruggable, but new efforts show some glimmers of hope. The drug Sotorasib has been approved by the FDA to target the KRAS G12C mutation. Here's a new item over at Nature …
|
|
|
|
|
|
|
